Literature DB >> 404320

The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions.

A Iio, W Strober, S Broder, S H Polmar.   

Abstract

Serum IgE concentrations were determined and IgE turnover studies were performed in control individuals as well as in patients with several disease states. Patients with common variable hypogammaglobulinemia, thymoma and hypogammaglobulinemia, ataxia telangiectasia, and selective IgA deficiency had significantly decreased mean serum IgE concentrations. In turnover studies, this was found to be due to decreased IgE synthesis. In spite of these depressed mean values, some patients with common variable hypogammaglobulinemia had normal serum IgE concentrations and synthetic rates. Patients with the Wiskott-Aldrich syndrome had a significantly elevated mean serum IgE concentration. In one of four patients studied with the turnover technique, a strikingly high IgE concentration was present and was associated with an elevated IgE synthetic rate. Three other patients had both normal serum IgE concentrations and synthetic rates. Patients with chronic lymphocytic leukemia had significantly decreased mean serum concentrations and synthetic rates for IgE. The depressed IgE synthesis was associated with a significantly prolonged IgE half-life. Patients with Hodgkin's disease had significantly increased serum IgE concentrations. One of three patients studied had a high serum IgE concentration and synthetic rate of IgE. The two other patients had normal serum IgE concentrations associated with normal synthetic rates. Finally patients with protein-losing enteropathy or familial hypercatabolic hypoproteinemia had normal IgE concentrations associated with normal IgE metabolic parameters. In these cases, the disorder in the catabolic rate was not severe enough to affect the total amount of circulating IgE because IgE normally has a very high fractional catabolic rate. In general, IgE levels in a variety of disease states were correlated with IgE synthetic rates and abnormalities in the catabolic rate of IgE in disease did not exert an important effect on IgE concentration.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404320      PMCID: PMC372281          DOI: 10.1172/JCI108695

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

2.  Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-globulin antibody.

Authors:  K Ishizaka; T Ishizaka; M M Hornbrook
Journal:  J Immunol       Date:  1966-12       Impact factor: 5.422

3.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

4.  The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition.

Authors:  R M Blaese; W Strober; R S Brown; T A Waldmann
Journal:  Lancet       Date:  1968-05-18       Impact factor: 79.321

Review 5.  Metabolism of immunoglobulins.

Authors:  T A Waldmann; W Strober
Journal:  Prog Allergy       Date:  1969

6.  IgE in immunodeficiency.

Authors:  S H Polmar; T A Waldmann; W D Terry
Journal:  Am J Pathol       Date:  1972-12       Impact factor: 4.307

7.  Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE concentration of patients with acquired hypogammaglobulinemia, thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal lymphangiectasia and Wiskott-Aldrich syndrome.

Authors:  T A Waldmann; S H Polmar; S T Balestra; M C Jost; R M Bruce; W D Terry
Journal:  J Immunol       Date:  1972-08       Impact factor: 5.422

8.  Serum IgE in immune deficiency disorders.

Authors:  P McLaughlan; D R Stanworth; A D Webster; G L Asherson
Journal:  Clin Exp Immunol       Date:  1974-03       Impact factor: 4.330

9.  Serum IgD and IgE concentrations in immunodeficiency diseases.

Authors:  R H Buckley; S A Fiscus
Journal:  J Clin Invest       Date:  1975-01       Impact factor: 14.808

10.  The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma.

Authors:  T A Waldmann; A Iio; M Ogawa; O R McIntyre; W Strober
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

View more
  6 in total

1.  Prediagnostic immunoglobulin E levels and risk of chronic lymphocytic leukemia, other lymphomas and multiple myeloma-results of the European Prospective Investigation into Cancer and Nutrition.

Authors:  Alexandra Nieters; Anna Łuczyńska; Susen Becker; Nikolaus Becker; Roel Vermeulen; Kim Overvad; Krasimira Aleksandrova; Heiner Boeing; Pagona Lagiou; Dimitrios Trichopoulos; Antonia Trichopoulou; Vittorio Krogh; Giovanna Masala; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Bas Bueno-de-Mesquita; Suzanne M Jeurnink; Elisabete Weiderpass; Eva Ardanaz; Maria-Dolores Chirlaque; María-José Sánchez; Soledad Sánchez; Signe Borgquist; Salma Butt; Beatrice Melin; Florentin Späth; Sabina Rinaldi; Paul Brennan; Rachel S Kelly; Elio Riboli; Paolo Vineis; Rudolf Kaaks
Journal:  Carcinogenesis       Date:  2014-09-30       Impact factor: 4.944

2.  Hypofibrinogenemia due to fibrin formation in subserosal type eosinophilic gastroenteropathy.

Authors:  E Presterl; L Wagner; W Base
Journal:  Clin Investig       Date:  1992-06

3.  Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels.

Authors:  S C Dreskin; P K Goldsmith; W Strober; L A Zech; J I Gallin
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

4.  Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).

Authors:  Monica G Lawrence; Thamiris V Palacios-Kibler; Lisa J Workman; Alexander J Schuyler; John W Steinke; Spencer C Payne; Emily C McGowan; James Patrie; Ramsay L Fuleihan; Kathleen E Sullivan; Patricia L Lugar; Camellia L Hernandez; Douglas E Beakes; James W Verbsky; Thomas A E Platts-Mills; Charlotte Cunningham-Rundles; John M Routes; Larry Borish
Journal:  J Clin Immunol       Date:  2018-02-17       Impact factor: 8.317

Review 5.  Diseases associated with immunosuppression.

Authors:  E R Heise
Journal:  Environ Health Perspect       Date:  1982-02       Impact factor: 9.031

6.  Immunomodulatory Effect of Mangiferin in Experimental Animals with Benzo(a)Pyrene-induced Lung Carcinogenesis.

Authors:  Peramaiyan Rajendran; Thangavel Jayakumar; Ikuo Nishigaki; Ganapathy Ekambaram; Yutaka Nishigaki; Jayabal Vetriselvi; Dhanapal Sakthisekaran
Journal:  Int J Biomed Sci       Date:  2013-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.